CareDx, Inc (NASDAQ:CDNA) Shares Purchased by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its position in shares of CareDx, Inc (NASDAQ:CDNA) by 31.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,760 shares of the company’s stock after buying an additional 7,085 shares during the period. Wells Fargo & Company MN owned 0.06% of CareDx worth $637,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CDNA. Plato Investment Management Ltd raised its position in CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after purchasing an additional 1,370 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of CareDx by 41.5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company’s stock worth $200,000 after buying an additional 2,742 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of CareDx during the fourth quarter worth about $208,000. Cornercap Investment Counsel Inc. acquired a new position in CareDx in the 4th quarter valued at about $214,000. Finally, Inceptionr LLC acquired a new stake in CareDx during the 4th quarter worth approximately $240,000.

Insider Activity at CareDx

In related news, Director Peter Maag sold 13,281 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total value of $228,831.63. Following the sale, the director now owns 316,743 shares of the company’s stock, valued at approximately $5,457,481.89. This represents a 4.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CDNA shares. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and decreased their price target for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group dropped their price target on shares of CareDx from $34.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, April 17th. HC Wainwright reduced their price objective on shares of CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, Stephens reissued an “overweight” rating and set a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, CareDx currently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

CareDx Trading Down 0.5 %

CDNA stock opened at $15.00 on Friday. The company has a market cap of $831.39 million, a price-to-earnings ratio of -5.56 and a beta of 2.18. The firm has a 50 day moving average of $18.49 and a 200-day moving average of $21.47. CareDx, Inc has a 12-month low of $9.44 and a 12-month high of $34.84.

CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. During the same period in the previous year, the business earned ($0.03) earnings per share. CareDx’s quarterly revenue was up 17.6% compared to the same quarter last year. Sell-side analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.